News blog

UK backs away from ‘value-based pricing’ for drugs

The UK government appears to have rowed back on plans for a radical new pricing system for medicines that would have used independent assessments of their worth to limit costs. But some elements of the pharmaceutical industry are still warning that a new agreement on how much the country pays for drugs will drive research overseas. 

BACK TO ARTICLE

Your details are incomplete or incorrect, please amend the following information

%s

Tell a Friend

Your friend's email address (Required)

Your email (Required)

Message subject (Required)

Message

Verify (Required)

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE